Felsher Dean W, Bradon Nicole
Division of Oncology, Departments of Medicine and Pathology, Stanford University, Stanford, California, USA.
Drug News Perspect. 2003 Jul-Aug;16(6):370-4. doi: 10.1358/dnp.2003.16.6.829309.
The overexpression of the MYC proto-oncogene has been implicated in the pathogenesis of most types of human cancer. Recent experimental observations indicate that the inactivation of MYC may be effective in the treatment of neoplasia. Several different strategies have been employed to develop novel drugs that may be effective to target the inactivation of MYC for the treatment of cancer. Some of these strategies are discussed.
MYC原癌基因的过表达与大多数类型的人类癌症发病机制有关。最近的实验观察表明，MYC的失活可能对肿瘤治疗有效。已经采用了几种不同的策略来开发可能有效靶向MYC失活以治疗癌症的新型药物。本文将讨论其中一些策略。
